0002007730-26-000001.txt : 20260203 0002007730-26-000001.hdr.sgml : 20260203 20260203163742 ACCESSION NUMBER: 0002007730-26-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260130 FILED AS OF DATE: 20260203 DATE AS OF CHANGE: 20260203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malabre Richard C CENTRAL INDEX KEY: 0002007730 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 26593772 MAIL ADDRESS: STREET 1: AKEBIA THERAPEUTICS, INC. STREET 2: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2026-01-30 false 0001517022 Akebia Therapeutics, Inc. AKBA 0002007730 Malabre Richard C C/O AKEBIA THERAPEUTICS, INC 245 FIRST ST. CAMBRIDGE MA 02142 false true false false SVP, Chief Accounting Officer false Common Stock 2026-01-30 4 A false 79000.00 0.00 A 348914.00 D Stock Option (Right to buy) 1.41 2026-01-30 4 A false 119000.00 0.00 A 2036-01-30 Common Stock 119000.00 119000.00 D The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. /s/ Carolyn M. Rucci, attorney-in-fact for Richard C. Malabre 2026-02-03